Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract analysis group (CRO) and a frontrunner in ion channel screening, immediately introduced the appointment of Dr Chris Mathes, MBA, as Chief Industrial Officer (CCO). Chris will work alongside the Firm’s knowledgeable management staff to drive industrial technique and lead world enterprise growth and advertising and marketing actions.
Following completion of Metrion’s £3.7M fairness financing in December 20231, the Firm has made a number of high-profile appointments2. Chris’ appointment as CCO additional strengthens the senior administration staff, enhancing its scientific and industrial capabilities, and proceed to drive growth in key world markets.
Chris is a well-respected business chief with over 25 years of expertise within the biopharmaceutical sector, specializing within the preclinical CRO house and growing high-performance gross sales and advertising and marketing methods. He has held a number of executive-level positions, at Sophion Bioscience, ChanTest (now a part of Charles River Laboratories), Icagen and AnaBios, the place he offered strategic assist to information enterprise growth and total technique. Over the previous few months Chris has additionally been advising Metrion on enterprise growth within the USA.
Chris holds a PhD in Neuroscience from the College of California, Los Angeles (UCLA) and an MBA from Rutgers College. He accomplished his post-doctoral analysis at Stanford College and the Max Planck Institute for Biophysical Chemistry, specializing in ion channel analysis and patch clamp expertise, and has printed 17 peer-reviewed papers on his work.
Dr Andrew Southan, Chief Government, Metrion Biosciences, stated: “Chris brings excellent industrial and scientific experience to Metrion’s senior administration staff. His expertise in main ion channel and preclinical drug discovery industrial operations globally is second to none. Chris provides depth to our neuroscience experience, additional strengthens our presence within the USA, and I’m assured he’ll make a considerable contribution in the direction of attaining Metrion’s imaginative and prescient of turning into the main preclinical ion channel service supplier.”
As a specialised CRO, Metrion has an excellent providing to assist preclinical drug discovery and security pharmacology analysis. I’m excited to hitch the business main staff, which additionally brings me again to my ion channel and Neuroscience roots, and I look ahead to working towards the Firm’s purpose of partnering with main biopharma firms globally, connecting them to our capabilities, assays and experience that translate to higher success in scientific trials.”
Dr Chris Mathes, CCO, Metrion Biosciences
